chloro-formic acid tetrahydrofurfuryl ester | 64661-06-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氧唑烯
• 英文名称: chloro-formic acid tetrahydrofurfuryl ester
• 英文别名: Chlor-ameisensaeure-tetrahydrofurfurylester；tetrahydrofuran-2-ylmethyl chloroformate；tetrahydrofurfuryl chloroformate；oxolan-2-ylmethyl carbonochloridate
• CAS: 64661-06-9
• 化学式: C₆H₉ClO₃
• mdl: MFCD20484240
• 分子量: 164.589
• InChiKey: JUEYJVZDCUZWDX-UHFFFAOYSA-N

物化性质

• 沸点：
  84-90 °C(Press: 8 Torr)
• 密度：
  1.245±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  10
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.833
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  chloro-formic acid tetrahydrofurfuryl ester 、 2-amino-1,2,3,4-tetrahydronaphthalene-2-carboxylic acid (4-diethylaminophenyl)amide 在 吡啶 作用下， 以 四氢呋喃 为溶剂， 以44%的产率得到tetrahydrofuran-2-ylmethyl 2-(((4-(diethylamino)phenyl)amino)carbonyl)-1,2,3,4-tetrahydronaphthalen-2-ylcarbamate
  参考文献：
  名称：

  Tetraline derivatives as ghrelin receptor modulators

  摘要：

  本发明涉及式(I)的化合物，或其在治疗上适宜的盐或前药，该化合物的制备，含有该化合物的组合物以及该化合物在预防或治疗由胃泌素调节的疾病中的应用，包括厌食症、癌症恶病质、进食障碍、与年龄相关的身体组成下降、体重增加、肥胖和糖尿病。

  公开号：

  US20050014794A1
• 作为产物：
  描述：

  四氢糠醇 、 三光气 在 喹啉 作用下， 以 二氯甲烷 、 甲苯 为溶剂， 生成 chloro-formic acid tetrahydrofurfuryl ester
  参考文献：
  名称：

  Tetraline derivatives as ghrelin receptor modulators

  摘要：

  本发明涉及式(I)的化合物，或其在治疗上适宜的盐或前药，该化合物的制备，含有该化合物的组合物以及该化合物在预防或治疗由胃泌素调节的疾病中的应用，包括厌食症、癌症恶病质、进食障碍、与年龄相关的身体组成下降、体重增加、肥胖和糖尿病。

  公开号：

  US20050014794A1

文献信息

• 5-amidino-2-hydroxybenzenesulfonamide derivatives medicinal compoistions containing the same medicinal use thereof and intermediates in the production thereof
  申请人：Uchida Masahiko

  公开号：US20050014787A1

  公开（公告）日：2005-01-20

  The present invention relates to a 5-amidino-2-hydroxybenzenesulfonamide derivative represented by the general formula: wherein R 1 is an optionally substituted lower alkyl group, an optionally substituted lower alkoxy group, an optionally substituted lower alkenyl group, a cycloalkyl group or a lower acyl group etc.; Q is a hydrogen atom or an optionally substituted lower alkyl group; and Z is a hydrogen atom or a hydroxy group etc., or a pharmaceutically acceptable salt thereof, which exert a potent and selective activated blood coagulation factor X inhibitory activity and is useful as an agent for the prevention or treatment of a disease occurred associating an activated blood coagulation factor X, a pharmaceutical composition comprising the same and an intermediate thereof. These compounds are useful as preventives or remedies for various diseases such as brain infarction, cerebral thrombosis, cerebral embolism, TIA, cerebral vascular jerk, Alzheimer's diseases, myocardial infarction, heart attack, heart failure, thrombosis, pulmonary infarction and pulmonary embolism.

  本发明涉及一种5-酰胺基-2-羟基苯磺酰胺衍生物，其通式表示为：其中，R1是可选取的取代的低烷基，可选取的取代的低烷氧基，可选取的取代的低烯基，环烷基或低酰基等；Q是氢原子或可选取的取代的低烷基；Z是氢原子或羟基等，或其药学上可接受的盐。该衍生物具有强效和选择性的激活血凝因子X抑制活性，可用作预防或治疗与激活血凝因子X相关的疾病的药物，以及包含该衍生物和其中间体的制药组合物。这些化合物可用作各种疾病的预防或治疗，例如脑梗死、脑血栓形成、脑栓塞、短暂性脑缺血发作、脑血管抽搐、阿尔茨海默病、心肌梗死、心脏病发作、心力衰竭、血栓形成、肺梗死和肺栓塞。
• 3-Mono-and 3,5-Disubstituted Piperidine Derivatives as Renin Inhibitors
  申请人：Baeschlin Daniel Kaspar

  公开号：US20080194629A1

  公开（公告）日：2008-08-14

  The invention relates to 3,5-piperidine compounds, these compounds for use in the diagnostic and therapeutic treatment of a warm-blooded animal, especially for the treatment of a disease (=disorder) that depends on activity of renin; the use of a compound of that class for the preparation of a pharmaceutical formulation for the treatment of a disease that depends on activity of renin; the use of a compound of that class in the treatment of a disease that depends on activity of renin; pharmaceutical formulations comprising a 3,5-piperidine compound, and/or a method of treatment comprising administering a 3,5-piperidine compound, a method for the manufacture of a 3,5-piperidine compound, and novel intermediates and partial steps for their synthesis. Especially, the 3,5-piperidine compounds have the formula I, wherein the symbols have the meanings described in the specification.

  本发明涉及3,5-哌啶化合物，这些化合物用于诊断和治疗温血动物，特别是用于治疗依赖肾素活性的疾病(=紊乱)；该类化合物用于制备用于治疗依赖肾素活性疾病的制药配方；该类化合物用于治疗依赖肾素活性的疾病；包括3,5-哌啶化合物的制药配方和/或包括给予3,5-哌啶化合物的治疗方法，一种制备3,5-哌啶化合物的方法，以及其合成的新中间体和部分步骤。特别地，3,5-哌啶化合物具有式I，其中符号具有规范中描述的含义。
• 5-AMIDINO-2-HYDROXYBENZENESULFONAMIDE DERIVATIVES, MEDICINAL COMPOSITIONS CONTAINING THE SAME, MEDICINAL USE THEREOF AND INTERMEDIATES IN THE PRODUCTION THEREOF
  申请人：Kissei Pharmaceutical Co., Ltd.

  公开号：EP1443041A1

  公开（公告）日：2004-08-04

  The present invention relates to a 5-amidino-2-hydroxybenzenesulfonamide derivative represented by the general formula: wherein R1 is an optionally substituted lower alkyl group, an optionally substituted lower alkoxy group, an optionally substituted lower alkenyl group, a cycloalkyl group or a lower acyl group etc.; Q is a hydrogen atom or an optionally substituted lower alkyl group; and Z is a hydrogen atom or a hydroxy group etc., or a pharmaceutically acceptable salt thereof, which exert a potent and selective activated blood coagulation factor X inhibitory activity and is useful as an agent for the prevention or treatment of a disease occurred associating an activated blood coagulation factor X, a pharmaceutical composition comprising the same and an intermediate thereof. These compounds are useful as preventives or remedies for various diseases such as brain infarction, cerebral thrombosis, cerebral embolism, TIA, cerebral vascular jerk, Alzheimer's diseases, myocardial infarction, heart attack, heart failure, thrombosis, pulmonary infarction and pulmonary embolism.

  本发明涉及由通式表示的 5-脒基-2-羟基苯磺酰胺衍生物： 其中 R1 是任选取代的低级烷基、任选取代的低级烷氧基、任选取代的低级烯基、环烷基或低级酰基等； Q 是氢原子或任选取代的低级烷基；以及 Z 是氢原子或羟基等、 或其药学上可接受的盐，它们具有强效和选择性的活化血液凝固因子 X 抑制活性，可用作预防或治疗与活化血液凝固因子 X 有关的疾病的药物、由其组成的药物组合物及其中间体。这些化合物可用于预防或治疗各种疾病，如脑梗塞、脑血栓、脑栓塞、TIA、脑血管痉挛、老年痴呆症、心肌梗塞、心脏病、心力衰竭、血栓形成、肺梗塞和肺栓塞。
• EP1443041
  申请人：——

  公开号：——

  公开（公告）日：——
• New esters of 5-acyl-8-hydroxyquinolines and their use for the control of fungi
  申请人：GEIGY AG J R

  公开号：US02875126A1

  公开（公告）日：1959-02-24